Open access · CC-BY
via OpenAlex
Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy
Dekun Liu, Napamanee Kornthong, Shuguang Yu, Jakkree Tangthianchaichana, Prasert Sobhon, Sha Yang
Cardiology Research and Practice · 2026
Deregulated nutrient-sensing
Cellular senescence
Altered intercellular communication
Chronic inflammation
Senolytics
Human
Mouse
Preclinical / animal
Review
Abstract
Atherosclerosis underlies most ischemic cardiovascular events, and its prevalence rises with population aging. Cellular senescence(definition) is increasingly implicated as a driver of plaque progression, although the causal evidence is largely preclinical. Senescent endothelial cells, smooth muscle cells, and macrophages acquire a senescence‐associated secretory phenotype (SASP), releasing cytokines, chemokines, proteases, and procoagulant factors. These factors sustain plaque inflammation, weaken the fibrous cap, and increase rupture risk. In this narrative review, we link SASP signaling to plaque instability through NF‐κB, p38 MAPK, mTOR(definition), NLRP3, and cGAS–STING signaling. We then evaluate tetramethylpyrazine (ligustrazine), quercetin, fisetin, resveratrol, and curcumin against an operational definition reserving senolytic and senomorphic for effects shown in confirmed senescent cells. On that standard, only quercetin and fisetin qualify; for the other three, the vascular evidence is anti‐inflammatory, antioxidant, or senescence‐preventive rather than directed at established senescent cells. Tetramethylpyrazine protects the endothelial glycocalyx and reduces plaque area in atherosclerotic rabbits. Dasatinib plus quercetin benefits ApoE−/− mice, whereas the only human evidence comes from quercetin monotherapy, which improved endothelium‐dependent vasodilation in vessels from symptomatic male, but not female, bypass patients ex vivo. Because senescence burden varies between individuals, we consider how multiomics profiling might stratify patients. The evidence remains mechanistic and hypothesis‐generating, with limited human cardiovascular interventional data: Much of it was recorded in cells never shown to be senescent, and no formulation has been shown to reach the human vessel wall. Targeting the SASP therefore requires trial evidence rather than an established basis for precision medicine.
◌ CITATION ONLY
Full text is not openly licensed for redistribution here. Read it at the source:
Provenance
- Source
- OpenAlex
- DOI
- 10.1155/crp/6765242
- Canonical
- link ↗
- Fetched
- 2026-11-13 MST
Cite this
APA
Liu, D., Kornthong, N., Yu, S., Tangthianchaichana, J., Sobhon, P., & Yang, S. (2026). Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy. <em>Cardiology Research and Practice</em>. https://doi.org/10.1155/crp/6765242
Vancouver
Liu D, Kornthong N, Yu S, Tangthianchaichana J, Sobhon P, Yang S. Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy. Cardiology Research and Practice. 2026. doi:10.1155/crp/6765242.
BibTeX
@article{dekun2026Senesc,
title = {Senescence‐Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product‐Based Interventions and Implications for Personalized Therapy},
author = {Dekun Liu and Napamanee Kornthong and Shuguang Yu and Jakkree Tangthianchaichana and Prasert Sobhon and Sha Yang},
journal = {Cardiology Research and Practice},
year = {2026},
doi = {10.1155/crp/6765242},
}
Research neighborhood
References, citing works, and semantically nearest findings. Click a node to open it.
Related findings
Cardiology research and practice 2026
Citation only
Senescence-Associated Secretory Phenotype (SASP) and Atherosclerotic Plaque Inflammation: Natural Product-Based Interventions and Implications for Personalized Therapy.
bioRxiv (Cold Spring Harbor Laboratory) 2025
Preprint · CC-BY
Senolytic treatment with fisetin reverses age-related endothelial dysfunction partially mediated by SASP factor CXCL12
Ageing research reviews 2026
Citation only
Intracranial aneurysms as a manifestation of premature vascular aging: Cellular senescence, inflammaging, and wall degeneration.
BMB Reports 2015
Open access · CC-BY
Invited Mini Review : From cell senescence to age-related diseases: differential mechanisms of action of senescence-associated secretory phenotypes
bioRxiv (Cold Spring Harbor Laboratory) 2024
Preprint · CC-BY
Senolytic therapy combining Dasatinib and Quercetin restores the chondrogenic phenotype of human osteoarthritic chondrocytes by promoting the release of pro-anabolic mediators
Aging Cell 2024
Open access · CC-BY